乾癬性關節炎市場 - KOL的考察

Psoriatic Arthritis - KOL Insight

出版日期: 2023年05月26日 | 出版商:

FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格

簡介目錄

本報告提供乾癬性關節炎市場相關調查分析，對已上市的治療方法和開發平台有的治療方法的KOL的考察。

抗腫瘤壞死因子劑
- 重要考慮因素摘要
Interleukin-17 抑制劑
- Cosentyx（蘇金單抗；諾華）
- Taltz（ixekizumab；禮來公司）
白血球介素 12/23、白血球介素 23 抑制劑
- Stelara（優特克單抗；Janssen）
- Tremfya（guselkumab；楊森）
- Skyrizi（risankizumab；艾伯維/勃林格殷格翰）
Janus 激? (JAK) 抑制劑
- Xeljanz（託法替尼；輝瑞）
- Rinvoq（upadacitinib；艾伯維）
4型環核?酸磷酸二酯?抑制劑
- Otezla（阿普斯特；安進）
T細胞活化抑制劑
- Orencia（阿巴西普；百時美施貴寶）

在研藥物

Interleukin-17 抑制劑
- Bimzelx（bimekizumab；UCB）
- Izokibep（Affibody/Acelyrin）
- Sonelokimab（MoonLake 免疫療法）
Interleukin-23 抑制劑
- Ilumya/Ilumetri（tildrakizumab；Almirall/Sun Pharmaceutical）
酪胺酸激? 2 (TYK2) 抑制劑
- Sotyktu（deucravacitinib；百時美施貴寶）
- TAK-279（武田）
TYK2/JAK-1 抑制劑
- Brepocitinib（Priovant Therapeutics）
絲裂原激活蛋白激?活化蛋白激? 2 抑制劑
- Zunsemetinib（Aclaris Therapeutics）

乾癬關節炎治療的未來趨勢與機會

附錄

新聞

簡介目錄

What clinical and commercial factors are influencing KOLs' prescribing decisions for Novartis' Cosentyx and Lilly's Taltz anti-IL-17 therapies? In the IL-23 inhibitor sector, how do rheumatologists assess the clinical advantages of Janssen's Tremfya and AbbVie/Boehringer Ingelheim's Skyrizi in patients with severe skin disease who have milder arthritis or IBD? KOLs critically assess the prospects of launched and pipeline therapies.

In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.

15 Jun 23 KOL Bulletin -- Views on the long-term Phase III data for UCB'S Bimzelx

16 Jun 23 KOL Bulletin -- Views on post-hoc analysis of Phase III COSMOS data for Janssen's Tremfya

Executive summary

Current and future treatment algorithm for psoriatic arthritis

Research objectives

Approved drugs

Anti-tumour necrosis factor agents
- Key insights summary
Interleukin-17 inhibitors
- Cosentyx (secukinumab; Novartis)
- Taltz (ixekizumab; Lilly)
Interleukin-12/23 and interleukin-23 inhibitors
- Stelara (ustekinumab; Janssen)
- Tremfya (guselkumab; Janssen)
- Skyrizi (risankizumab; AbbVie/Boehringer Ingelheim)
Janus kinase (JAK) inhibitors
- Xeljanz (tofacitinib; Pfizer)
- Rinvoq (upadacitinib; AbbVie)
Type 4 cyclic nucleotide phosphodiesterase inhibitors
- Otezla (apremilast; Amgen)
T-cell activation inhibitors
- Orencia (abatacept; Bristol Myers Squibb)

Pipeline drugs

Interleukin-17 inhibitors
- Bimzelx (bimekizumab; UCB)
- Izokibep (Affibody/Acelyrin)
- Sonelokimab (MoonLake Immunotherapeutics)
Interleukin-23 inhibitors
- Ilumya/Ilumetri (tildrakizumab; Almirall/Sun Pharmaceutical)
Tyrosine kinase 2 (TYK2) inhibitors
- Sotyktu (deucravacitinib; Bristol Myers Squibb)
- TAK-279 (Takeda)
TYK2/JAK-1 inhibitor
- Brepocitinib (Priovant Therapeutics)
Mitogen-activated protein kinase-activated protein kinase-2 inhibitor
- Zunsemetinib (Aclaris Therapeutics)